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ABSTRACT 
 
BACKGROUND: More than a decade since its inception, the benefits and cost-
efficiency of robot-assisted radical prostatectomy (RARP) continue to elicit controversy. 
 
OBJECTIVE: To compare outcomes and costs of RARP vs. open RP (ORP). 
 
DESIGN, SETTING AND PARTICIPANTS: A cohort study of 629,593 men who 
underwent RP for localized prostate cancer at 449 hospitals in the United States from 
2003 to 2013, using the Premier Hospital Database. 
 
INTERVENTION: RARP was ascertained through a review of the hospital charge 
description master for robotic supplies.  
 
OUTCOME MEASURES AND STATISTICAL ANALYSIS: 90-day postoperative 
complications (Clavien), blood product transfusions, operating room time, length of stay 
and direct hospital costs. Propensity-weighted regression analyses accounting for 
clustering by hospitals and survey weighting ensured nationally representative 
estimates. 
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RESULTS AND LIMITATIONS: Utilization of RARP grew rapidly from 1.8% in 2003 to 
85% in 2013 (p<0.001). RARP patients (n=311,135) were less likely to experience any 
complications (OR 0.68, p<0.001), prolonged LOS (OR 0.28, p<0.001), or receive blood 
products (OR 0.33,p =0.002) compared to ORP patients (n=318,458). RARP’s adjusted 
mean ORT was 131 min (p=0.002) longer. 90-day direct hospital costs were higher for 
RARP (+$4528, p<0.001), primarily attributed to operating room and supplies costs. 
Costs were no longer signficantly different between ORP and RARP among the highest 
volume surgeons (≥104 cases/year) (+$1990, p=0.40) and highest volume hospitals 
(≥318 cases/year) (+$1225, p=0.39) Limitations included lack of oncologic 
characteristics and the retrospective nature of the study. 
 
CONCLUSIONS: Our contemporary analysis found that RARP confers a perioperative 
morbidity advantage at higher costs. In the absence of large randomized trials due to 
the widespread adoption of RARP, this retrospective study represents the best available 
evidence for the morbidity and cost profile of RARP vs. ORP. 
 
PATIENT SUMMARY: In this large study of men with prostate cancer who underwent 
either open or robotic radical prostatectomy, we found robotic surgery had a better 
morbidity profile, but costs more.  
 
 5 
INTRODUCTION 
 
Prostate cancer is the commonest non-skin malignancy and the second leading cause 
of cancer death among men in the United States (US) [1]. Radical prostatectomy (RP) is 
an established treatment modality for localized prostate cancer [2], associated with a 
survival advantage compared to watchful waiting [3]. In the past decade, robot-assisted 
radical prostatectomy (RARP has rapidly disseminated in the US largely driven by 
extensive patient-directed marketing and inter-hospital competition to offer the latest 
technology. Despite RARP’s rapid adoption, there exists no large-scale randomized 
controlled trial demonstrating its superiority over open RP (ORP) [4,5]. Instead, the best 
evidence has so far come from observational cohort studies and meta-analyses [6,7]. 
The latest comparative study of 5,915 Medicare patients treated with either ORP or 
RARP between 2008 and 2009, found no differences in complications, readmissions 
and additional cancer therapies, but a benefit with regard to blood transfusions and 
length of stay (LOS) [8]. Another National Inpatient Sample (NIS) study across the same 
time period included 19,462 patients of all age groups and insurance status found that 
RARP had decreased rates of intra- and postoperative complications [9]. 
 
In light of these inconclusive findings regarding RP’s morbidity profile, we sought to re-
examine the perioperative outcomes and costs of RARP compared to ORP, 
hypothesizing that RARP would be associated with better morbidity but higher costs. 
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PATIENTS AND METHODS 
 
Data source 
We analyzed data from Premier Hospital Database (Premier, Inc., Charlotte, NC), a 
nationally representative all-payer dataset capturing over 45 million hospital inpatient 
discharges, representing approximately 20% of all hospitalizations in the US. Premier’s 
data has been validated and used in previous landmark studies [10,11]. We received 
institutional review board exemption for this study. 
 
Hospital-specific projection weights are applied to each discharge to project the sample 
to a national estimate of inpatient discharges. Premier’s projection methodology was 
validated by the Food and Drug Administration in 2001; it is based upon a stratified 
comparison of Premier’s inpatient database to all US hospitals responding to the 
American Hospital Association Annual Survey and validated through a comparison to 
projections using the National Hospital Discharge Survey. Hospital-level projection 
weights are then applied to each discharge in the Premier database. All numbers 
reported herein refer to projected estimates. 
 
Study cohort and main exposure 
Using International Classification of Diseases, Ninth Revision (ICD-9) codes, we 
identified men diagnosed with prostate cancer (185) who underwent RP (60.5) between 
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2003 and 2013.  Men with metastatic disease (196.x, 197.x, 198.x) and other 
malignancies (140.x to 209.79) were excluded. Patients who had a code for a robot-
assisted procedure (ICD-9 17.42 or 17.44 introduced in October 2008) or a recorded 
charge code for robotic instrumentation were classified as RARP. These charge codes 
were obtained through a thorough review of the charge description master (CDM) 
specifically identifying supplies unique to robotic procedures, via a combination of 
flagging every item in the EndoWrist® Instrument and Assessory Catalog from Intuitive 
Surgical® and manual review, similar to the methodology described in a previous study 
[11]. We excluded the limited proportion of non-robotic, laparoscopic RPs 
(n=27,619;4.2%) in order to have a comparison between ORP and RARP only. 
 
Covariates 
We examined relevant patient, hospital, and surgical characteristics: (1) patient 
characteristics included age (<55, 55-64, 65-74, ≥75 years), race (White, Black, 
Hispanic, other/unknown), marital status (married, non-married), insurance status 
(Medicare, Medicaid, private, other/unknown), and CCI (0, 1, ≥2); (2) hospital 
characteristics included teaching status, hospital size (<400, 400-600 or >600 beds), 
location (urban or rural), and geographical region (Midwest, Northeast, South or West); 
(3) surgical characteristics included year of procedure, type of surgical approach 
(robotic vs. open) and annual surgeon and hospital volume. Annual surgical volume was 
calculated based on the annual number of RP performed, irrespective of surgical 
approach. In the absence of clear cut-off references [12], we defined the highest volume 
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as ≥75th percentile (highest quartile), as other authors have done [13-15]: for surgeon 
volume: ≥104 cases per year, i.e. ≥2 cases per week and for hospital volume: ≥318 
cases/year, i.e. nearly 1 case per day. 
 
Endpoints 
We used ICD-9 codes to identify events defined by the Clavien classification system, 
including events not present at the time of the admission for RP but occurring during the 
index hospital stay and/or on re-admission to the hospital within 90 days of the 
procedure[16]. Patients with events managed in the outpatient setting were not 
captured. Complications were classified as any (Clavien grade 1-5) or major (Clavien 
grade 3-5). Clavien grade 5 denoted mortality and was identified through disposition 
codes., Our methodology met 7 out of the 10 Martin criteria according to European 
Association of Urology guidelines [17]. 
 
We utilized the CDM to determine the number of units of blood product utilized and, 
operating room time (ORT). ORT indicates actual ORT instead of time from incision to 
closure, allowing inference about operating room (resource) utilization (“wheels in, 
wheels out”) rather than the speed of the surgeon (e.g. robotic console time). Hospital 
LOS (days) was directly captured by the database, indicating the period from admission 
to discharge. Prolonged LOS was defined as LOS >median of 2-days. 
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Total expenditure associated with surgery were estimated using 90-day direct hospital 
costs for each patient. These consisted of the actual cost to treat the patient, including 
supplies, labor, depreciation of equipment etc., and included variable (direct) and fixed 
costs(overhead). The capital costs and annual maintenance fees associated with the 
robotic platform were not included; these fixed costs per case are dependent on the 
specific type of robotic unit as well as the amortization of these costs based on the 
frequency and duration of use, [18,19] none of which is reliably available in the current 
database. To facilitate comparison, all costs were adjusted to 2014 US dollars using the 
Consumer Price Index.  
 
Statistical analyses 
Using descriptive statistics, we compared baseline characteristics of ORP vs. RARP 
using chi-square (categorical) and Mann-Whitney (continuous) tests. For continuous 
outcomes (LOS, ORT and 90-day direct hospital costs), differences between ORP and 
RARP were found to have a gamma distribution, so we constructed generalized linear 
regression models. Postoperative blood tranfusions were analyzed both as categorical 
(yes/no) and count variables (number of units of blood products). For categorical 
outcomes, we performed logistic regression to estimate the odds ratios [ORs] of the 
outcome for RARP compared to ORP. Negative binomial regression was used for blood 
products (number of units) when analyzed as count variables.  
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To minimize selection bias, we employed propensity scores to control for potential 
confounders between ORP and RARP patients; these included all characteristics listed 
in the “Covariates” paragraph. Each patient was weighted by the inverse propensity of 
being treated by ORP or RARP [20]. The propensity of being “assigned” to either ORP 
or RARP was calculated using multivariable logistic regression models based on the 
above confounders. To account for inter-hospital variability, we adjusted for clustering of 
patients within hospitals [21]. There was no missing data. To examine if surgical volume 
or time period of surgery exerted any effect modification on the type of procedure (ORP 
vs. RARP), we examined the significance of interaction terms and subsequently 
performed subgroup analyses accordingly.  Statistical analyses were performed using 
SAS 9.3 (SAS Institute, NC) and reported in accordance to European Urology 
guidelines [22]. All tests were two-sided and a p-value of <0.05 was considered 
statistically significant. 
 
Threshold Analysis 
Since prior studies have shown that surgical volume is inversely related to ORT [23], 
complications and positive surgical margins for robotic procedures [24], we performed a 
threshold analysis with a deterministic model using TreeAge Pro Suite 2015 (TreeAge 
Software, Inc., Williamstown, MA) to identify the clinical scenario achieving a cost 
advantage for RARP over ORP. We used inputs from our statistical models and varied 
the values of modificable variables (ORT, annual surgical volume, and complication 
rates) for RARP vs. ORP.  
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RESULTS 
 
Study Cohort 
The final propensity-weighted study cohort comprised of 629,593 men who underwent 
either ORP or RARP at 449 US hospitals. Pre- and post-propensity-weighted 
characteristics are summarized in Table 1.  
 
Over the study period, 311,135 (49.4%) RPs were performed with robotic assistance. 
The proportion of RARP increased steadily across the years, from 1.8% in 2003 to 9.8% 
in 2004 (“Innovation Phase”), 21.8% in 2005 to 35.4% in 2007 (“Early Adopter Phase”), 
47.8% in 2008 to 76.5% in 2010 (“Early Majority Phase”), and 81.0% in 2011 to 85.6% 
in 2013 (“Late Majority Phase”) (p <0.0001) (Figure 1). 
 
Perioperative Outcomes 
Unadjusted outcomes are shown in Table 2 and Appendix Table 1. After accounting 
for confounding variables, RARP was found to have a 32% decreased odds of 90-day 
complications (OR: 0.68, 95% confidence interval [CI]: 0.55–0.83,p<0.001). There were 
no significant difference in 90-day major complication rates (OR: 1.00, 95% CI: 0.73 to 
1.38, p=0.99). RARP patients were also less likely to receive intra- or post-operative 
blood products (OR: 0.33, 95% CI: 0.19 to 0.59,p<0.001). RARP was associated with a 
longer adjusted mean ORT (+131 minutes, 95% CI: +48 to +213,p=0.002). The 
magnitude of difference between ORP and RARP was less pronounced among the 
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highest volume surgeons (+32 minutes, 95% CI: +5 to +59, p=0.02) and hospitals (+43 
minutes, 95% CI: +5 to +81, p=0.03). Analyses stratified according to time periods were 
performed and our results were generally consistent with the main analyses (Table 3). 
 
Costs 
RARP was associated with higher 90-day direct hospital costs (RARP vs. ORP: $14,897 
vs. $9558, adjusted difference: +$4,528, 95% CI: $2,928 to $6,127, p<0.001), hugely 
driven by supplies (RARP vs. ORP: $4,267 vs. $1,089, adjusted difference: +$5,545,  
95% CI: $3,904 to $7,187, p<0.001) and OR costs (RARP vs. ORP: $7,013 vs. $4,529, 
adjusted difference: +$3,146,  95% CI: $1,592 to $4,700, p<0.001) (Figure 2). The 
shorter mean length of stay in RARP patients (RARP vs. ORP: 1.71 vs. 2.95, adjusted 
difference: -0.75 days, 95% CI: -0.99 to -0.50, p<0.001) corresponded with the 
significant decrease in room and board costs (RARP vs. ORP: $1,885 vs. $2,264, 
adjusted difference: -$784, 95% CI: -$1,384 to -$181, p<0.001). Subgroup analyses 
showed that cost-differences between ORP and RARP were no longer significant 
among the highest-volume surgeons (p=0.15) and hospitals (p=0.39) (Table 3).  
 
Threshold Analysis 
Annual surgical volume and ORT were among the most influential factors on RARP 
costs while a change in the probability of any complication (Clavien ≥1) had a modest 
impact. With multi-way sensitivity analysis, we estimated that at an average 
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complication rate of 9.53%, an annual surgeon volume of 20 cases/year, for RARP to 
cost less than ORP, the ORT taken for the entire RARP to complete would have to be 
≤152 minutes. Assuming an annual hospital volume of 126 cases/year, our results 
remained similar; the ORT taken for RARP would have to be ≤156 minutes. The 
relationship of ORT with annual surgeon volume or hospital volume on 90-day direct 
hospital costs for ORP vs. RARP are shown in Figures 3a and 3b, respectively. 
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DISCUSSION 
Our contemporary population-based study demonstrated rapid adoption of RARP 
between 2003 and 2013 in accordance to the Law of Diffusion of Innovation [25]. RARP 
was also associated with decreased morbidity compared to ORP, while incurring 
significantly higher costs. This current study expanded upon the findings of the latest 
cohort studies, which were limited to a little more than a year’s data between October 
2008 and December 2009 [8,9]. Our results confirmed that patients undergoing RARP 
experienced less overall postoperative complications, although this morbidity advantage 
did not extend into the major complications category. 
 
Comparison with previous studies 
In the current healthcare climate of cost-containment, examining expenditures is 
imperative in healthcare technology assessment. The higher costs for RARP (>$5000) 
compare well with single-institutional studies reporting a $4,300 loss per RARP case 
when considering both direct and indirect costs [26]. Another study revealed that the 
median direct cost was about $2000 more for RARP than ORP, with the main 
differences in surgical supply (RARP: $2015; ORP: $185) and operating room (RARP: 
$2798; ORP: $1611;p<0.001) costs [27]. This was consistent with the findings in our 
study, i.e. robotic surgery-specific supplies and operating room costs were the main 
contributors to higher costs for RARP (Figure 2). This may be a potential target for cost-
containment initiatives, with greater commercialization and mass production. It is also 
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important to note that our costs analyses did not include the initial fixed cost of acquiring 
the robot, which can cost up to $2.5 million, and ongoing maintenance and repair costs. 
It was estimated that when the amortized cost of the robot itself was included, the 
additional total cost of performing RARP (over ORP) was up to $4800 in 2007 in the US 
[18]. A more recent economic model in Australia found the incremental cost per RARP 
case compared with ORP was $1,933 for the da Vinci Si model [19]. 
 
Robotic surgery proponents assert that reduced LOS results in decreased costs; we 
indeed found that RARP conferred a shorter LOS than ORP, translating into room and 
board costs savings. Additionally, it is possible that there may be an unmeasured 
benefit associated with decreased convalescence and earlier return to work for RARP 
patients [28].  
 
With prostate cancer being the commonest male solid organ malignancy, reducing its 
economic burden on the healthcare system is paramount. Our study suggests that 
reducing ORT and having the surgery performed by a higher volume surgeon or 
hospital would substantially decrease RARP costs; the development of a postoperative 
complication had a less pronounced impact on costs. While our analysis did not include 
the fixed costs associated with acquiring the robotic platform in the first place, our 
analysis clearly demonstrated that a marked decrease in ORT was necessary to make 
RARP cost-competitive with ORP. Given that surgical volume is associated with surgical 
efficiency [12], we speculated that high-volume surgeons were more likely to surmont 
the learning curve, improve procedural efficiency, and sufficiently reduce their ORT to 
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justify the elevated costs associated with RARP. Our data also demonstrated that cost 
differences between ORP and RARP were no longer significantly different among the 
highest volume surgeons and hospitals, supporting centralization to high-volume 
providers, as advocated for major cancer surgery [29]. However, in the context of the 
United States, this may be difficult given that over 85% of RPs are already performed 
via the robotic approach, and robotic training has disseminated through increasing 
resident involvement [30,31].  
 
This study represented the largest comparative analysis of RARP vs. ORP. By relying 
on CDM to identify supplies unique to robotic surgery, we provided the first true 
temporal trend analysis of RARP utilization in the US. Previous studies relied on ICD-9-
CM or CPT procedural codes and showed a surge in minimally invasive RP in late 
2008, which may have been simply attributed to the emergence of a dedicated robotic 
surgery procedural code. Indeed, a recent cross-analysis of NIS and Premier’s data 
suggest that up to 39% of RARPs may be miscoded as ORPs in the NIS [32]. Our 
combined approach to identify RARP allowed us to provide an accurate comparison of 
RARP vs. ORP from the early adoption (2003-2004) to the late majority (2011-2013) 
periods rather than a mere snapshot of a constrained period [6,9]. Indeed, two large 
studies on temporal trends in the adoption and outcomes of minimally-invasive 
surgeries for prostatectomy have found lower postoperative complication rates for 
minimally-invasive procedures as compared to ORP over time [33,34]. Another notable 
strength of our analysis is that we reported direct 90-day hospital costs, which better 
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represeted true resource utilization, compared to cost–to-charge ratios, as required by 
other datasets (e.g., NIS) [35], which may not accurately depict true costs. This is 
fundamental in evaluating robotic surgery’s cost-efficiency.  
 
Limitations 
This study has several limitations. Firstly, our study was only based on a sampling of 
hospitals in the US. We employed clustered statistical analyses while accounting for 
survey weights [21], similar to prior population-based studies to reduce sampling bias 
[9,16,33]. Secondly, our secondary analysis of administrative data is subject to potential 
misclassification bias of postoperative complications. Consequently, the minor 
complication rate (Clavien 1-2) in our cohort may be underestimated. However, our 
results mirror those of previously reported grade 1-2 complication rates.[7] Additionally, 
both RARP and ORP are subject to the same bias thus permitting a valid comparison. 
Another limitation is that the IPTW employed to reduce selection bias may accentuate 
unmeasured confounders such as oncologic characteristics such as PSA and TNM 
stages [36], which were not available in this dataset.  
 
Additionally, despite accounting for year of surgery, we are unable to fully account for 
other changes over time which may lead to differences in outcomes between ORP and 
RARP. For example, there have been refinements in surgical technique and approach 
for RARP which could also account for better outcomes [37]. More profoundly, our 
results do not reflect underlying quality of care initiatives that might have been 
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implemented to improve outcomes. For example, data from universal healthcare 
systems have suggested that standardized care pathways have increased the efficiency 
of post-operative benchmark measures auch as LOS without compromising 
complications or readmission rates [38]. Given the large differences in our outcomes 
between ORP and RARP, it is quite plausible that these findings are at least partly 
explanined by these unmeasured confounders rather than the surgical approach alone.  
 
Furthermore, our study’s short follow-up precluded us from evaluating important long-
term endpoints such urinary incontinence, erectile dysfunction and cancer-specific 
survival. A previous study had found higher rates of incontinence and erectile 
dysfunction among men who underwent minimally invasive RP compared to ORP; this 
may represent the early experience of RARP (data from 2003 to 2007). Nevertheless 
these 2 important complications need to be emphasized to all patients undergoing 
RARP. Additionally relying on diagnosis codes for functional outcomes do not inform 
severity of the condition; the same code for urinary incontinence may refer to either a 
patient using 1 security pad a day for stress incontinence or a severely incontinent 
patient who uses numerous pads a day [39]. Lastly, health-related quality of life 
assessment was not available for comparison; a nationwide evaluation using the Health 
Professionals Follow-up Study found no significant differences in health-related quality 
of life between ORP and RARP [40]. 
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CONCLUSIONS 
Our contemporary population-based study showed a rapid adoption of RARP between 
2003 and 2013 in the US. RARP was found to have decreased morbidity compared to 
ORP, in particular lower 90-day postoperative complication rates, blood transfusion 
rates and decreased LOS, even among multimorbid patients. RARP had higher 90-day 
direct hospital costs, attributable to higher supplies and operating room costs. This cost 
difference with ORP was not apparent among the highest volume surgeons. Future 
updated comparative analyses using cost-effectiveness analysis may be of value by 
incorporating outcomes, quality of life, and costs of ORP and RARP [41].
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FIGURE LEGENDS 
 
Figure 1. Trend Of Surgical Approach For Radical Prostatectomy In The United States From 2003 
to 2013 
 
Figure 2. Adjusted Cost Comparisons Of Open Radical Protatectomy (ORP) And Robot-Assisted 
Radical Prostatectomy (RARP) In The United States From 2003 To 2013, Including Costs 
Breakdowns  
 
Figure 3a .The Relationship Between Operating Room Time And Annual Surgeon Volume On 90-
Day Direct Hospital Costs For Open Radical Protatectomy (ORP) Versus Robot-Assisted Radical 
Prostatectomy (RARP) In The United States. The light grey regions indicate the parameters for 
which RARP will be cheaper compared to ORP 
 
Figure 3b. The Relationship Between Operating Room Time And Annual Hospital Volume On 90-
Day Direct Hospital Costs For Open Radical Protatectomy (ORP) Versus Robot-Assisted Radical 
Prostatectomy (RARP) In The United States. The light grey regions indicate the parameters for 
which RARP will be cheaper compared to ORP 
